

bs-6318R**[Primary Antibody]**

Bioss
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

Acid sphingomyelinase Rabbit pAb

— DATASHEET —

Host: Rabbit
Clonality: Polyclonal
GeneID: 6609
Target: Acid sphingomyelinase
Immunogen: KLH conjugated synthetic peptide derived from human Acid sphingomyelinase: 201-300/629.
Purification: affinity purified by Protein A
Concentration: 1mg/ml

Isotype: IgG**SWISS:** P17405

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
 Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Converts sphingomyelin to ceramide. Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. Isoform 2 and isoform 3 have lost catalytic activity.
 Involvement in disease: Defects in SMPD1 are the cause of Niemann-Pick disease type A (NPDA) ; also known as Niemann-Pick disease classical infantile form. It is an early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.


Applications: **WB** (1:500-2000)
IHC-P (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
Flow-Cyt (2ug/Test)

Reactivity: Human, Mouse, Rat
 (predicted: Rabbit, Pig, Cow, Dog)


Predicted MW.: 64 kDa

Subcellular Location: Cytoplasm


— VALIDATION IMAGES —



Sample: HepG2(human) cell Lysate at 30 ug
 MCF-7(human) cell Lysate at 30 ug A431(human)
 cell Lysate at 30 ug Hale(human) cell Lysate at 30
 ug Primary: Anti- Acid sphingomyelinase
 (bs-6318R) at 1/300 dilution Secondary:
 IRDye800CW Goat Anti-Rabbit IgG at 1/20000
 dilution Predicted band size: 64kD Observed
 band size: 69 kD



Paraformaldehyde-fixed, paraffin embedded
 (Rat brain); Antigen retrieval by boiling in
 sodium citrate buffer (pH6.0) for 15min; Block
 endogenous peroxidase by 3% hydrogen
 peroxide for 20 minutes; Blocking buffer (normal
 goat serum) at 37°C for 30min; Antibody
 incubation with (Acid sphingomyelinase)
 Polyclonal Antibody, Unconjugated (bs-6318R)
 at 1:400 overnight at 4°C, followed by operating
 according to SP Kit(Rabbit) (sp-0023)
 instructions and DAB staining.



Blank control:A431. Primary Antibody (green
 line): Rabbit Anti-Acid sphingomyelinase
 antibody (bs-6318R) Dilution: 2µg /10⁶ cells;
 Isotype Control Antibody (orange line): Rabbit
 IgG . Secondary Antibody : Goat anti-rabbit IgG-
 PE Dilution: 1µg /test. Protocol The cells were
 fixed with 4% PFA (10min at room
 temperature) and then permeabilized with 0.1%
 PBST for 20 min at room temperature. The cells
 were then incubated in 5%BSA to block non-
 specific protein-protein interactions for 30 min
 at room temperature .Cells stained with Primary
 Antibody for 30 min at room temperature. The
 secondary antibody used for 40 min at room
 temperature. Acquisition of 20,000 events was

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

performed.

— SELECTED CITATIONS —

- **[IF=6.02]** Bodas M et al. Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis.(2018) Free Radic Biol Med.131:81-97. FCM ;Human. 30500419
- **[IF=6.126]** Peñate T et al. Lipid-Iron Nanoparticle with a Cell Stress Release Mechanism Combined with a Local Alternating Magnetic Field Enables Site-Activated Drug ReleaseCancers (Basel).2020 Dec 14;12(12):3767. IHC ;Mouse. 33327621
- **[IF=6.081]** Tuula Penate Medina. et al. Utilizing Sphingomyelinase Sensitizing Liposomes in Imaging Intestinal Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis. Biomedicines. 2022 Feb;10(2):413 IHC ;Human. 35203622
- **[IF=2.87]** Anastasia M. Ravodina. et al. Facile Cholesterol Loading with a New Probe ezFlux Allows for Streamlined Cholesterol Efflux Assays. Acs Omega. 2020;5(36):23289–23298 WB ;Mouse. 32954180